• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Lorcaserin does not increase rate of cardiovascular events in overweight or obese patients

byDayton McMillan
September 25, 2018
in Cardiology, Chronic Disease, Gastroenterology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. At a median follow-up of 3.3 years, rates of composite cardiovascular events in at-risk overweight or obese patients treated with lorcaserin were not significantly worse than for placebo treated patients.

2. Lorcaserin treated patients had significantly greater weight loss at 1 year compared to placebo treated patients.

Evidence Rating Level: 1 (Excellent)     

Study Rundown: Rates of obesity have drastically increased around the world in recent decades. Associated conditions which cause significant morbidity and mortality such as diabetes and stroke have risen alongside obesity. In addition to dietary and activity lifestyle modifications, pharmaceutical treatments could serve as an important treatment for overweight and obese patients. The 5-hydroxy-tryptamine 2C serotonin receptor agonist lorcaserin alters appetite and is of interest for treatment of overweight and obese patients. The CAMELLIA–TIMI 61 (Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients–Thrombolysis in Myocardial Infarction 61) trial investigated long-term cardiovascular and metabolic safety of lorcaserin in overweight patients with cardiovascular disease. The primary outcome of major cardiovascular events at a median follow-up of 3.3 years showed patients randomized to lorcaserin had similar outcomes as placebo treated patients. Weight loss of greater than 5% occurred in significantly more lorcaserin patients at 1 year.

Strengths of this study include its randomized design, detailed adverse event reporting, and inclusion of patients with multiple cardiac risk factors. Limitations include access to diet and exercise support during the study which is not generalizable to most patients, absent description of proportion of muscular or fat changes during weight loss, and absent reporting of weight loss comparisons at 3.3 years of follow-up. Overall, this study provides strong support to the cardiovascular safety of an important adjuvant therapy for weight loss in overweight or obese patients.

Click to read the study in NEJM

Relevant Reading: Multicenter, placebo-controlled trial of lorcaserin for weight management

RELATED REPORTS

2 Minute Medicine Rewind January 23, 2023

Weekly semaglutide associated with reduced BMI in adolescents with obesity

Fecal microbiota transplantation not associated with weight loss in bariatric surgery patients

In-Depth [randomized controlled trial]: Patients were recruited and randomized to study groups from 2014 to 2015. Eligible patients had a body mass index (BMI) of at least 27 and had one or more cardiovascular risk factors. Patients were treated with lorcaserin (n=6000) or placebo (n=6000) and followed for a median of 3.3 years. Over half of all patients studied had diabetes, hypertension, hyperlipidemia, or atherosclerotic cardiovascular disease. Discontinuation of patients in the study occurred at approximately 12% per year in both study groups. At 1 year, the mean change in weight from baseline was -4.2kg in the lorcaserin group and -1.4kg in the placebo group (P<0.001). Weight loss of at least 5% or 10% at 1 year occurred in a greater proportion of treated patients compared to placebo patients (P<0.001 for both comparisons). The primary outcome of major cardiovascular events occurred in 2.0% of patients per year in the treatment group and 2.1% of patients per year in the placebo group (hazard ratio [HR], 0.99; 95% confidence interval [CI], 0.85 to 1.14; P<0.001 for noninferiority). Incidence of serious adverse events was similar between both groups. Of patients who had both baseline and 1-year cardiac echocardiograms performed, worsening valvulopathy occurred in 1.8% and 1.3% of treated and placebo patients, respectively (P=0.24).

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Lorcaserinobesity
Previous Post

2 Minute Medicine Rewind September 24, 2018

Next Post

Current guidelines may not provide adequate instruction for prescribing anticoagulation in patients with atrial fibrillation

RelatedReports

Many new pediatric asthma cases attributable to obesity
Weekly Rewinds

2 Minute Medicine Rewind January 23, 2023

January 23, 2023
Nearly Half of All Pediatric Buprenorphine Exposures Result in Hospitalization
Chronic Disease

Weekly semaglutide associated with reduced BMI in adolescents with obesity

December 26, 2022
Many new pediatric asthma cases attributable to obesity
Chronic Disease

Fecal microbiota transplantation not associated with weight loss in bariatric surgery patients

December 22, 2022
Many new pediatric asthma cases attributable to obesity
Chronic Disease

Treatment with semaglutide in patients with obesity may be associated with weight loss

November 11, 2022
Next Post
Bystander and first-responder initiated CPR associated with improved outcomes

Current guidelines may not provide adequate instruction for prescribing anticoagulation in patients with atrial fibrillation

Estimated costs of clinical trials for FDA approval of novel therapeutics

Appropriate use criteria for angiography may frequently miss obstructive coronary artery disease

Atorvastatin loading before percutaneous coronary intervention improves outcomes in patients with acute coronary syndrome

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • BNT162b2 booster is safe and reduces COVID-19 transmission in older adults
  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options